Navigation Links
Surgery reduces risk of mortality due to prostate cancer even for low-risk groups

A Swedish research team partly consisting of researchers from Uppsala University followed a group of prostate cancer patients in the Nordic region for 15 years. The study found, among other things, that surgery reduces the risk that men with prostate cancer (even those with low-risk tumours) will die within 15 years. The results were published today in the New England Journal of Medicine.

The researchers followed Swedish, Finnish and Icelandic prostate cancer patients. Radical prostatectomy (surgical removal of the prostate gland) was performed on 347 randomly chosen male patients, while "watchful waiting" (careful monitoring combined with hormone treatment in cases of disease progression) was pursued with respect to 348 others. The men averaged 65 years of age when diagnosed with prostate cancer.

The results, which were analysed every third year, have significantly impacted how patients are treated today, both nationally and internationally. The study represents the only randomised investigation thus far to demonstrate that surgery reduces the risk of mortality from prostate cancer. The majority of the men had palpable tumours; 12 percent had non-palpable tumours that could only be identified using PSA (a marker for prostate cancer).

After 15 years, 48 per cent of the men in the surgical group had died, against 58 per cent in the watchful-waiting group. Of patients in the surgical group, 16 per cent died due to prostate cancer, against 23 per cent in the watchful-waiting group. The risk of cancer spreading beyond the prostate gland was 12 per cent lower for those who received surgery.

It was primarily younger men who benefitted from surgery. Analysis on the basis of age groups showed that men younger than 65 benefitted most. Among older men, there was no significant difference between the surgical group and the watchful-waiting group, presumably due to the fact that older men run a greater risk of mortality due to other illnesses, on account of which a much larger study would be required to show any difference.

The researchers also studied a group of men with tumours of the least aggressive kind (a low-risk group), even there finding differences in survival rate depending on whether surgery was performed. The low-risk group in question cannot, however, be perfectly compared with currently defined low-risk groups, and better markers will be required to determine the likelihood that low-risk tumours will assume a more aggressive form.

"The study shows that surgery reduces the risk of mortality due to prostate cancer, even for men with low-risk tumours," says Anna Bill-Axelson, chief physician at the Department of Surgical Sciences at Uppsala University. "But not everybody benefits from surgery, so individual risks and potential gains have to be assessed on the basis of age, other illnesses, tumour type and patient preferences."

Another finding of the study is that that surgical patients whose tumours had grown beyond the prostate gland ran a seven-times-greater risk of mortality due to prostate cancer than those whose tumours were limited to the prostate gland. The former group can greatly benefit from adjuvant treatment such as radiation therapy.

The most common side effects of surgical treatment were impotence and incontinence. More patients in the watchful-waiting group required ameliorative treatment due to tumor progression (hormone therapy) after a number of years. Both early side effects due to surgery and late side effects due to ameliorative treatment impact the quality of life of patients and must be part of discussions with patients about treatment options.

The study, designated "SPCG-4" (Scandinavian Prostate Cancer Group Study 4) was financed by the Swedish Cancer Society and, in recent years, also by the National Institutes of Health in the US.

A major study similar to the SPCG-4 study is currently under way in the US, with results expected soon. Another large study, comparing surgical, radiation-therapeutic and watchful-waiting outcomes in connection with localised prostate cancer, is under way in the UK.


Contact: Anna Bill-Axelson
Uppsala University

Related medicine news :

1. Repeated Weight-Loss Surgery Carries Added Risks
2. The New Liposuction Technique Means No Surgery or Suction
3. Research validates surgery alone offers reasonable overall survival for stage I SCLC
4. "New Cosmetic Surgery" Journalism Prize
5. Abington Memorial Hospital Welcomes Vakil to Orthopaedic Surgery Division
6. Drug for advanced kidney cancer shrinks tumors prior to surgery
7. Abington Memorial Hospital Earns Two Designations: Blue Distinction Center for Spine Surgery(SM) and Blue Distinction Center for Knee and Hip Replacement(SM)
8. New endoscopic treatment may spare Barretts esophagus patients from surgery
9. Pittsburgh Neurosurgeons Explore Use of Drug that Illuminates Brain Tumor Cells To Guide Surgery
10. Surgery Alone May Thwart Stage 1 Lung Cancer
11. Comparison shows robot-assisted option offers advantages for kidney surgery
Post Your Comments:
(Date:6/26/2016)... ... 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop ... The fitness app plans to fix the two major problems leading the fitness industry today:, ... all type program , They don’t eliminate all the reasons people quit their ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
Breaking Medicine Technology: